FABP4 plasma levels are increased in familial combined hyperlipidemia.
The lipid profile of familial combined hyperlipidemia (FCHL) shares some characteristics with atherogenic dyslipidemia seen in diabetes, metabolic syndrome, and obesity. Adipocyte fatty acid-binding protein 4 (FABP4) appears to be a determinant of atherogenic dyslipidemia. We examined relationships between FABP4 plasma concentrations, dyslipidemia, and metabolic variables in patients with FCHL. We studied 273 unrelated FCHL patients and 118 control subjects. FABP4 was higher in FCHL than controls, with mean levels of 21.8 (10.1) microg/l and 19.2 (9.2) microg/l, respectively (adjusted P= 0.012). In FCHL, FABP4 correlated to body mass index (BMI), waist circumference, insulin levels, and homeostasis model assessment (HOMA) index (all P< 0.05), but not to lipid levels, whereas in obese patients, FABP4 correlated to triglyceride levels (r = 0.303, P= 0.014) and very low density lipoprotein size (r = 0.502, P = 0.001), as determined by nuclear magnetic resonance. Associations of FABP4 with BMI and waist circumference, but not with insulin levels, persisted in this subgroup. Plasma FABP4 does not influence the lipid phenotype of FCHL. In a small subgroup of obese FCHL, FABP4 levels were associated with triglyceride-rich lipoproteins independent of insulin resistance. These results support a hyperlipidemic mechanism of FCHL different from similar metabolic conditions where fat mass is strongly related to FABP4 and hypertriglyceridemia.
Cabré
Anna
A
Unitat de Recerca de Lípids i Arteriosclerosi, Universitat Rovira i Virgili, Servei de Medicina Interna, Hospital Universitari Sant Joan de Reus Reus, Spain.
Lázaro
Iolanda
I
Cofán
Montserrat
M
Jarauta
Estibaliz
E
Plana
Núria
N
Garcia-Otín
Angel L
AL
Ascaso
Juan F
JF
Ferré
Raimón
R
Civeira
Fernando
F
Ros
Emilio
E
Masana
Lluís
L
D015331:Cohort Studies; D050556:Fatty Acid-Binding Proteins / Q000097:blood*; D005260:Female; D006801:Humans; D006950:Hyperlipidemia, Familial Combined / Q000097:blood* / Q000453:epidemiology / Q000378:metabolism; D050356:Lipid Metabolism; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D008875:Middle Aged
C493410:FABP4 protein, human; D050556:Fatty Acid-Binding Proteins
Eur Heart J. 2008 Dec;29(24):2959-71
18775919
J R Soc Med. 2002;95 Suppl 42:46-53
12216327
Cell. 2008 Sep 19;134(6):933-44
18805087
Diabetes Care. 2007 Oct;30(10):2667-72
17620449
Arterioscler Thromb Vasc Biol. 2004 Jan;24(1):167-74
14551155
AIDS. 2004 Mar 26;18(5):819-21
15075521
Circulation. 2007 Mar 27;115(12):1537-43
17389279
J Lipid Res. 2008 Aug;49(8):1746-51
18421072
Clin Chem. 2006 Mar;52(3):405-13
16423904
Atherosclerosis. 2008 Jul;199(1):147-53
17983623
Circulation. 2004 Sep 14;110(11):1492-8
15353487
Diabetologia. 1985 Jul;28(7):412-9
3899825
Circulation. 2004 Jun 15;109(23 Suppl 1):III2-7
15198959
FASEB J. 2005 Dec;19(14):2063-5
16219805
Diabetes. 2008 Aug;57(8):2022-7
18469202
J Lipid Res. 2005 Nov;46(11):2398-404
16106049
J Clin Invest. 1993 Feb;91(2):448-55
8432854
J Biol Chem. 2005 Apr 1;280(13):12888-95
15684432
Metabolism. 1976 Mar;25(3):313-20
1250165
Arterioscler Thromb. 1993 Jun;13(6):804-14
8499400
Atherosclerosis. 2007 Nov;195(1):e150-8
17553506
Eur J Clin Invest. 1980 Apr;10(2 Pt 1):161-72
6780364
Arterioscler Thromb Vasc Biol. 2007 Aug;27(8):1796-802
17510463
Circulation. 2004 Jan 27;109(3):433-8
14744958
Nat Med. 2001 Jun;7(6):699-705
11385507
Diabetes. 2006 Sep;55(9):2541-8
16936202
Am J Cardiol. 2003 Aug 18;92(4A):27J-33J
12957324
Metabolism. 1998 May;47(5):508-13
9591739
J Lipid Res. 2002 Jun;43(6):930-5
12032168